Navigation Links
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Date:10/15/2008

12 Patient Trial Targets Advanced Solid Tumors, Including Lung Cancer

SAN FRANCISCO, Oct. 15 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) today announced the completion of treatment for the first patient cohort in the Phase 1 cancer clinical trial of its targeted poxvirus JX-594, delivered by intravenous (IV) infusion. No significant toxicities were reported, and treatment was well-tolerated.

The Phase 1 IV trial involves treatment of patients with advanced, metastatic solid tumors refractory to standard therapy. Patients receive treatment at one of five dose levels in a sequential dose-escalating design; the first cohort has now been treated safely. Once the maximum tolerated dose is defined, an additional three to six patients will be enrolled at that dose level. The trial is being conducted initially at clinical sites in the United States, and will subsequently open at sites in Canada. "We're very excited to have this trial open and enrolling with our lead product, JX-594. The safe delivery of JX-594 through intravenous administration is a major milestone for our Company," said David H. Kirn, M.D., President and Chief Executive Officer of Jennerex. "IV therapy allows treatment of major market cancers including non-small cell lung cancer. These data confirm the safety and feasibility of systemic dosing and tumor targeting that were reported in liver tumor patients treated previously."

The primary objective for this trial is to determine the maximum tolerated and/or feasible dose of JX-594 administered IV. In addition, IV delivery of JX-594 to solid tumors will be evaluated. An estimated total of 12 to 15 patients will be treated.

About JX-594

JX-594 is a cancer biotherapeutic product, currently in Phase 2 trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types on three Phase 1 trials; treat
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014   DaVita HealthCare Partners Inc. ... the nation,s largest and most innovative health care ... – the company,s award-winning, leadership development and cultural ... teammates from around the globe were in attendance ... Academy is a two-day one-of-a-kind experience for new ...
(Date:10/16/2014)... (Nasdaq: CPHD ) today reported revenues for ... growth of 15% from $100.1 million for the third ... of 2014 was $(7.2) million, or $(0.10) per share, ... $(0.02) per share, in the third quarter of 2013.  ... debt discount and transaction costs, and amortization of purchased ...
(Date:10/16/2014)... -- Eight finalists, all representing outstanding innovation in pediatric ... for a chance to compete for one of two ... Second Annual Pediatric Surgical Innovation Symposium hosted by ... 24, 2014. Selected from a competitive field ... internationally, the finalists are: , Creative ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4
... TAMPA, Fla., April 16, 2007 /PRNewswire/ -- ... that it has received orphan drug designation ... its anti-viral therapy,ganciclovir, for the treatment of ... by Laboratoires Thea in Europe under,the brand ...
... - Data Presented at 2007 APA Meeting ... -- Data,from four new studies examining safety ... (SNRI) being studied as a potential treatment ... presented today at the,2007 American Psychiatric Association ...
Cached Medicine Technology:Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:10/18/2014)... 2014 Stafford Communications , a ... the breast cancer awareness program called “Sleep Pink” on ... pink pajama parties where women and men can promote ... support of the program, Stafford’s employees wore pink pajamas ... Facebook Page. In exchange, Stafford Communications and the makers ...
(Date:10/18/2014)... 2014 Asbestos Likely More Widespread Than ... more widespread than previously thought, with newly discovered sources ... asbestos-rich areas are in locations not previously considered to ... be presented at the Annual Meeting of the Geological ... 20 October. , “These minerals were found where one ...
(Date:10/18/2014)... Australia (PRWEB) October 19, 2014 ... in Australia provide professional carpet cleaning services, ... Carpets are typically professionally cleaned every one to ... Flores, “Demand for industry services plummeted during the ... delayed discretionary services, including professional carpet cleaning.” The ...
(Date:10/18/2014)... Globally, the demand for antioxidants ... in the years to come. The projected growth ... of antioxidants remained surprisingly strong during the period ... all business sectors across the globe. Geographically, the ... followed by North America and China. Among the ...
(Date:10/18/2014)... One major trend upcoming in this market is ... making efforts to encourage people to donate organs. The ... process more transparent and easy. , Analysts forecast the ... at a CAGR of 16.85 percent over the period ... drivers in the market is an increase in the ...
Breaking Medicine News(10 mins):Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 2Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 3Health News:Asbestos Likely More Widespread Than Previously Thought 2Health News:Asbestos Likely More Widespread Than Previously Thought 3Health News:Carpet Cleaning Services in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Carpet Cleaning Services in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Global Antioxidants Industry Opportunities & 2018 Trends Now Available at MarketReportsOnline.com 2Health News:Global Antioxidants Industry Opportunities & 2018 Trends Now Available at MarketReportsOnline.com 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4
... Call for Tough Physical/Mental Stimulus PlanORLANDO, Fla., March ... and fitness programs during the American Alliance for ... in Tampa, March 31-April 4 2009GeoFitness has developed ... the rapper Rikshaw to launch the nationwide "Get ...
... Complies with Updated Interoperability RequirementsWATKINSVILLE, Ga., March ... Information Technology (CCHIT(R)) today announced that Silk ... a CCHIT Certified(R) 08 Ambulatory EHR, and ... (EHR) criteria for office-based use. Ambulatory EHRs ...
... by Mark Senak, Senior Vice President at Fleishman-Hillard in Washington, D.C., posts ... Web 2.0 policy development providing insight into FDA,s point of view about ... pharmaceutical industry. , ... Washington, DC (PRWEB) March 17, 2009 -- Today ...
... by the Stanley Medical Research Institute and Johns Hopkins ... neurotic behavior in infected men and women. Between 25 ... 30 percent of the U.S. population - may be infected.Toxoplasma ... passed to humans when changing cat litter, gardening and petting. ...
... Cooperative, one of the largest non-profit cooperative group purchasing and ... strategic sourcing services, announce their integrated partnership today. This partnership ... , ... Erie, PA (PRWEB) March 17, ...
... The medical costs that businesses pay to care for ... for nearly a dozen healthy, full-term infants, according to new ... medical cost for healthy full-term babies from birth through their ... than $3,800 is paid for by health plans, according to ...
Cached Medicine News:Health News:GeoFitness Launches 'Get Moving America' Campaign to Improve Youth Health 2Health News:Silk Information Systems's Silk V 4.2 Receives 08 CCHIT Certification 2Health News:Silk Information Systems's Silk V 4.2 Receives 08 CCHIT Certification 3Health News:FDA's DDMAC Provides Insight on Pharmaceutical Companies and Web 2.0 in Eye on FDA Podcast 2Health News:Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans 2Health News:MAGNET Cooperative and Procurex, Inc. Announce Integration Partnership Streamlining the Healthcare Industry's Purchasing Process 2Health News:MAGNET Cooperative and Procurex, Inc. Announce Integration Partnership Streamlining the Healthcare Industry's Purchasing Process 3Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: